AstraZeneca China Partner Granted Marketing Authorization for Anemia Drug
22 Agosto 2019 - 9:14AM
Dow Jones News
By Oliver Griffin
AstraZeneca PLC (AZN.LN) on Thursday said its partner in China
has received marketing authorization for roxadustat for treatment
of anemia caused by chronic kidney disease in patients who are
non-dialysis dependent.
The pharmaceutical company said FibroGen (China) Medical
Technology Development Co., Ltd. was granted marketing
authorization by China's National Medical Products Administration
and was supported by a Phase III trial.
AstraZeneca said marketing authorization follows the earlier
approval in China for roxadustat, which was granted in December,
for use by patients who are on dialysis.
The company and its partner expect to launch roxadustat in China
during the second half of 2019.
Write to Oliver Griffin at oliver.griffin@dowjones.com;
@OliGGriffin
(END) Dow Jones Newswires
August 22, 2019 02:59 ET (06:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
